BEAM Beam Therapeutics Inc.
Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Beam Therapeutics Inc. (BEAM) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New regulatory risk: FDA orphan drug and regenerative medicine advanced therapy designations granted for BEAM-302 in 2025, triggering expanded clinical trial and regulatory requirements
- • Updated clinical risk: BEACON trial interim data on BEAM-101 showed sustained mean total Hb increase to 15.6 g/dL at month six, with no Grade 3+ adverse events reported
Quarterly Financial SummaryXBRL
Revenue
$10M
Net Income
-$113M
Operating Margin
-1307.6%
Net Margin
-1162.4%
ROE
-11.7%
Total Assets
$1.3B
Source: XBRL data from Beam Therapeutics Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Beam Therapeutics Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.